A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
A phase 2 trial of MRG003, Capecitabine, Docetaxel in nasopharyngeal carcinoma, run by Lepu Biopharma Co., Ltd., active and no longer recruiting.
Overview
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma is a phase 2 interventional study registered as NCT05126719 by Lepu Biopharma Co., Ltd., with 238 participants planned, started 2023-04-06 and due to reach its primary completion in 2024-12-30. Interventions recorded: MRG003, Capecitabine tablets, Docetaxel injection. Conditions listed: Recurrent or Metastatic Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin
Shares MRG003, Lepu Biopharma, Nasopharyngeal carcinoma, Docetaxel.
- TrialA Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
Shares MRG003, Lepu Biopharma.
- TrialA Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)
Shares Nasopharyngeal carcinoma, Capecitabine, Docetaxel.
- TrialA Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Shares Capecitabine, Docetaxel.